|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
California Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing CaliforniaLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Abide Therapeutics Inc.
| | | Phone: | (858) 427-2590 | Year Established: | 2011 | Employees: | 10 | Main Contact: | Alan Ezekowitz MBChB, D.Phil., FAAP, Co-Founder, President & CEO | | Other Contacts: | Stan Blackburn, CFO Julianne Hunt, Ph.D., Executive Director, Scientific Operations Iain Fraser, MBChB, D.PHIL., VP, Early Clinical Development Cheri Grice, Ph.D, VP, Chemistry Gary O’Neill, Ph.D., Senior VP, Research
| | Company Description | Abide Therapeutics is focused on developing innovative medicines that target serine hydrolases, one of the largest enzyme classes in nature with validated but mostly untapped therapeutic potential. Serine hydrolases play important regulatory roles in human physiology and disease. Abide has created a proprietary platform, based on technology developed at The Scripps Research Institute by Professors Ben Cravatt and Dale Boger, that specifically targets serine hydrolases with selective small molecules. The ability to target and modulate serine hydrolases has potential to develop new medicines in many therapeutic areas. | |
|
|
|
|
|